Research programme: cancer therapeutics - Syros Pharmaceuticals

Drug Profile

Research programme: cancer therapeutics - Syros Pharmaceuticals

Alternative Names: Cyclin-dependent kinase 7 inhibitors; SY 351; SY-1365; THZ1; THZ531

Latest Information Update: 18 Nov 2016

Price : $50

At a glance

  • Originator Syros Pharmaceuticals
  • Developer Dana-Farber Cancer Institute; Syros Pharmaceuticals; Whitehead Institute for Biomedical Research
  • Class
  • Mechanism of Action Cyclin-dependent kinase inhibitors; Cyclin-dependent kinase-activating kinase inhibitors; Gene expression modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Breast cancer; Ewing's sarcoma; Neuroblastoma; Small cell lung cancer

Most Recent Events

  • 14 Nov 2016 Syros Pharmaceuticals plans a phase I trial for solid tumours, including triple-negative breast cancer, ovarian cancer and small cell lung cancer in ,
  • 10 Jun 2016 Pharmacodynamics data for SY 1365 from a preclinical study in Acute Myeloid Leukaemia presented at the 21st Annual Congress of the European Haematology Association (EHA-2016)
  • 20 Apr 2016 Syros Pharmaceuticals announces intention to submit IND application for SY-1365
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top